RBC Capital analyst Luca Issi maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback